A comparison of invasive lobular carcinoma with other invasive breast cancers at Tygerberg Academic Hospital

• Published in: South African journal of surgery Vol. 60; no. 3; pp. 176 - 181
• Main Authors: De Jager, LJ, Schubert, PT, Baatjes, K, Conradie, W, Edge, J
• Format: Journal Article
• Language: English
• Published: Pinelands Medpharm Publications 01.09.2022
• Subjects: Breast cancer; Cancer; Carcinoma; combined hormonal replacement therapy; Comparative analysis; Drug therapy, Combination; Hormone replacement therapy; Hormone therapy; Invasive lobular carcinoma; South Africa
• ISSN: 0038-2361; 2078-5151
• DOI: 10.17159/2078-5151/SAJS3768

Background: The second most common histological subtype of invasive breast carcinoma is invasive lobular carcinoma (ILC) occuring with a frequency 10–15% in Western countries and approximately 5%, in Africa, the Middle East and Asia (AMA). Combined hormone replacement therapy (CHRT) is a risk factor for the development of ILC which is infrequently diagnosed at our centre.This study aimed to investigate the incidence and clinicopathological characteristics of ILC as compared to invasive breast carcinoma of no special type (IBC-NST).Methods: Clinical and pathological data on breast carcinoma patients attending the breast and endocrine unit at Tygerberg Academic Hospital since 2017 have been recorded on a Stellenbosch University REDCap® database.Results: IBC-NST was the most frequent subtype diagnosed (83.9%) and ILC the second most common subtype (5.2%). Most ILCs were of luminal B intrinsic subtype, and the median size was slightly smaller than IBC-NST. There were significantly more grade 2 ILCs than IBC-NSTs (81.5% vs 50.9%). There was no statistical difference between stage and histological subtype.Conclusion: ILC has clinicopathological differences when compared to IBC-NST, although these were less pronounced in this study. The prevalence of ILC was similar to numbers reported in AMA. We hypothesise that there may be a discrepancy in the prevalence of ILC between public and private healthcare systems in South Africa, and that it may be due to differing trends in prescribing CHRT.